Dioxaphetyl butyrate
Dioxaphetyl butyrate (INN; trade names Amidalgon, Spasmoxal) is an opioid analgesic which is a diphenylacetic acid derivative, related to other open-chain opioid drugs such as dextropropoxyphene, levacetylmethadol (LAAM), lefetamine and dimenoxadol.[1][2]
Clinical data | |
---|---|
Other names | Amidalgon, Spasmoxal |
Routes of administration | Oral, Other ROA Unknown |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.006.731 |
Chemical and physical data | |
Formula | C22H27NO3 |
Molar mass | 353.462 g·mol−1 |
3D model (JSmol) | |
| |
| |
|
It produces similar effects to other opioids, including dependence, euphoria, analgesia, sedation, constipation, dizziness and nausea.[3]
In the United States it is a Schedule I Narcotic controlled substance with an ACSCN of 9621 and a 2013 annual aggregate manufacturing quota of zero.[4]
References
- PubChem. "Dioxaphetyl butyrate". pubchem.ncbi.nlm.nih.gov. Retrieved 2019-06-03.
- "Dioxaphetyl butyrate | C22H27NO3 | ChemSpider". www.chemspider.com. Retrieved 2019-06-03.
- "dioxaphetyl butyrate". drugcentral.org. Retrieved 2019-06-03.
- "Misuse of Drugs Act : Legislative history · Part I Class A · Section 1(a): Explicitly named Class A substances". isomerdesign.com. Retrieved 2019-06-03.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.